[Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Second addendum to Project A25-89]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018014817
German
Original Title: Acalabrutinib (Mantelzell-Lymphom; Kombination mit Bendamustin und Rituximab) - 2. Addendum zum Projekt A25-89
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/g25-34.html
Year Published: 2025
URL for published report: https://www.iqwig.de/download/g25-34_acalabrutinib_2-addendum-zum-projekt-a25-89_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/G25-34
MeSH Terms
  • Lymphoma, Mantle-Cell
  • Antineoplastic Agents
  • Tyrosine Kinase Inhibitors
  • Rituximab
  • Bendamustine Hydrochloride
  • Antineoplastic Combined Chemotherapy Protocols
Keywords
  • Acalabrutinib
  • Bendamustine Hydrochloride
  • Rituximab
  • Lymphoma – Mantle-Cell
  • Epidemiology
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.